NFATC2 and neoplasm: When Kaplan-Meier analysis was performed based on cytoplasmic expression of NFATc2, the 69 patients whose tumor was positive for NFATc2 in the cytoplasm had significantly better survival than the 21 patients whose tumor was negative for NFATc2 in the cytoplasm (Fig. 7E), with the median survival being 66.6 months versus 44.8 months (Table S4).